UniQure stock crashes over 50% today after FDA says Huntington’s therapy data isn’t enough - here's what investors need to know
QURE stock price today: UniQure NV's stock plummeted over 54% after the FDA deemed the clinical data for its Huntington's disease gene therapy AMT-130 inadequate. Investors are left questioning the future of the therapy and the broader gene therapy pipeline.
QURE stock price today: UniQure NV's stock plummeted over 54% after the FDA deemed the clinical data for its Huntington's disease gene therapy AMT-130 inadequate. Investors are left questioning the future of the therapy and the broader gene therapy pipeline.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
